Phathom Pharmaceuticals (PHAT) as of March 31, 2026 presents a deeply negative liquidation posture. Total assets of $305.1M are overwhelmed by total liabilities of $642.1M, producing book equity of negative $337.0M before applying any liquidation haircuts. Under a liquidation lens, recoverable assets are limited: cash and restricted cash of ~$183.8M recovers at par (100%); receivables of $80.7M apply at 90-95% (~$72-77M); inventory of $25.6M (current $6.5M + noncurrent $19.1M) recovers at 60% (~$15M); PP&E of $1.0M recovers at 50-70% (~$0.5-0.7M); and intangibles/ROU assets receive zero recovery. Gross liquidation asset recovery is approximately $272-277M. Against this, liabilities at face value total $642.1M, including: current liabilities of $125.0M (dominated by $83.3M AccruedLiabilitiesCurrent—which includes the current portion of the Revenue Interest Financing Agreement liability of $33.0M), non-current Revenue Interest Financing Agreement obligation of $347.9M, Hercules term loan net carrying value of $163.7M (face $175.0M, maturity February 2029), and other non-current liabilities of $3.5M (final payment fee accrual) plus operating lease obligations of $2.6M. The Revenue Interest Financing Agreement is the single largest liability: $347.9M noncurrent plus $33.0M current = $380.9M face, with investors entitled to aggregate payments equal to 200% of the $275M Investment Amount ($550M total cap), of which only $23.1M has been paid. In a liquidation scenario, the agreement's minimum amount provisions and potential default acceleration clauses (1.65x or 2.0x Investment Amount less payments already made) would crystallize substantial additional claims. The Hercules Loan Agreement carries a senior security interest in substantially all assets including IP, meaning cash and receivables would flow to Hercules first. The result is estimated equity recovery of negative $365-370M under conservative liquidation assumptions—confirming materially negative recovery to common stockholders. The MFFAIS-reported latest cash liquidation value of negative $109.8M and liquid liquidation value of negative $29.0M likely understate the structural deficit because the Revenue Interest Financing Agreement's noncurrent liability ($347.9M) may not be fully incorporated in those calculations. Compared to the prior 10-K filing (year-end 2025), the material changes this quarter were: (1) refinancing of the Hercules facility via the Fifth Amendment on February 25, 2026, replacing a PIK+cash structure with a $175M all-cash facility at Prime+3.10% (floor 9.85%), extending maturity to February 2029 and eliminating PIK interest; (2) partial debt extinguishment loss of $0.8M on the refinancing; (3) January 2026 equity offering generating $122.0M net proceeds, bolstering cash from what was a lower base at year-end; and (4) $229.0M repayment of the prior Hercules obligation. Operating cash burn improved materially QoQ—negative $15.6M in Q1 2026 vs. negative $84.9M in Q1 2025—driven by the $40.5M reduction in SG&A and doubled revenue to $58.3M. Despite the operating improvement trajectory, the Revenue Interest Financing Agreement's face obligation ($380.9M combined current and noncurrent carrying value) combined with the Hercules term loan ($163.7M net) places total funded debt-like liabilities at approximately $545M against a recoverable asset base well below that figure.
▼ Community Notes